February 27, 2018

Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders

Englewood Cliffs, NJ (February 27, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ FIRST NORTH; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that Proposal 4 – Ratification of the Reverse Stock Split set forth in the Company’s Definitive Proxy Statement filed with the […]

Keep Reading

PRESS RELEASE February 27, 2018

Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders

Englewood Cliffs, NJ (February 27, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that Proposal 4 – Ratification of the Reverse Stock Split set forth in the Company’s Definitive Proxy Statement filed with the Securities […]

Keep Reading

February 20, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

5 of 6 proposals pass with shareholder approval Meeting adjourned solely with respect to Proposal 4 – Ratification of the Reverse Stock Split Company outlines key corporate and clinical milestones for 2018  Englewood Cliffs, NJ (February 20, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ FIRST NORTH; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel […]

Keep Reading

PRESS RELEASE February 20, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

5 of 6 proposals pass with shareholder approval Meeting adjourned solely with respect to Proposal 4 – Ratification of the Reverse Stock Split Company outlines key corporate and clinical milestones for 201 Englewood Cliffs, NJ (February 20, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents […]

Keep Reading

February 8, 2018

Immune Pharmaceuticals to be Delisted from Nasdaq Stockholm

Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases (the “Company”) announced today that the Disciplinary Board of Nasdaq Stockholm has decided to delist the Company’s shares. Trading of the Company’s shares on Nasdaq First North will be discontinued on March 29, […]

Keep Reading

February 6, 2018

Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

Englewood Cliffs, NJ- February 6, 2018 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at the BIO CEO & Investor Conference, to be held February 12-13 at the New York Marriott Marquis in […]

Keep Reading

PRESS RELEASE February 6, 2018

Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

Englewood Cliffs, NJ- February 6, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at the BIO CEO & Investor Conference, to be held February 12-13 at the New York Marriott Marquis in New York, […]

Keep Reading

PRESS RELEASE January 26, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting

Annual Meeting to Resume Thursday, February 15, 2018 Englewood Cliffs, NJ – January 26, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it adjourned its Annual Meeting of Stockholders, scheduled for and convened on January 25, 2018. The […]

Keep Reading

January 26, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting

Annual Meeting to Resume Thursday, February 15, 2018 Englewood Cliffs, NJ – January 26, 2018 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it adjourned its Annual Meeting of Stockholders, scheduled for and convened on January 25, […]

Keep Reading